Rocket Pharmaceuticals (RCKT) Stock Target Reduced Following Q3 2025 Update on Cash Position

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the stocks that will double in 2026. Earlier on November 18, BofA lowered the firm’s price target on Rocket Pharmaceuticals to $8 from $10 and kept a Buy rating on the shares following an updated cash position that was made after the company announced its Q3 2025 update.

In its Q3 2025 earnings report, Rocket Pharmaceuticals maintained a strong financial foundation, with cash, cash equivalents, and investments totaling ~$222.8 million as of the quarter end. This cash position is expected to provide an operational runway into Q2 2027, excluding potential future proceeds from a Priority Review Voucher/PRV that may be granted upon KRESLADI approval. The company also significantly reduced its net loss and operating expenses year-over-year. The net loss for Q3 was $50.3 million, or $0.45 per share (basic and diluted), a marked improvement from the Q3 2024 net loss of $66.7 million, or $0.71 per share.

Rocket Pharmaceuticals achieved a critical milestone in its AAV cardiovascular gene therapy portfolio by successfully aligning with the FDA to lift the clinical hold on its pivotal Phase 2 trial of RP-A501 for Danon disease in under three months. Beyond Danon disease, engagement with the FDA is ongoing to align on the pivotal Phase 2 trial design for RP-A601 (for PKP2-ACM). Furthermore, Phase 1 trial start-up activities are underway for RP-A701 (for BAG3-DCM), with the first-in-human multi-center, dose-escalation study details found under NCT identifier NCT07137338. In the lentiviral portfolio, the BLA resubmission for KRESLADI (marnetegragene autotemcel; marne-cel) for severe LAD-I was accepted by the FDA, with a PDUFA target action date set for March 28, 2026.

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT), together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the US.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.